LAVIE 100 MG 150 ML SOLUTION

Indications

Approved Uses

Epilepsy: adjunctive therapy for partial-onset (focal) seizures; myoclonic seizures in juvenile myoclonic epilepsy; and primary generalized tonic-clonic seizures in idiopathic generalized epilepsy (age cutoffs depend on local labeling).

Dosage & Administration

Dosing by Condition

Adults (immediate-release): start 500 mg twice daily; increase by 500 mg twice daily every 2 weeks as needed/tolerated; usual max 3000 mg/day. Pediatric dosing is weight-based and indication/age-specific (e.g., focal seizures from 1 month of age; JME from ≥12 years; PGTC from ≥6 years per many labels).

Initial Dose

500 mg twice daily for adults and adolescents 16 years of age and older.

Maintenance Dose

1000 mg to 3000 mg per day, administered in two divided doses.

Maximum Dose

3000 mg/day (adults); 60 mg/kg/day (pediatric patients 4 years to <16 years)

Children's Dosage

Dosing is weight-based. Partial-onset seizures: 1 to <6 months: 7 mg/kg twice daily, up to 21 mg/kg twice daily. 6 months to <4 years: 10 mg/kg twice daily, up to 25 mg/kg twice daily. 4 to <16 years: 10 mg/kg twice daily, up to 30 mg/kg twice daily. Primary generalized tonic-clonic seizures (6 to <16 years): 10 mg/kg twice daily, up to 30 mg/kg twice daily.

Dose Adjustment Notes

Dose adjustment is required in renal impairment based on creatinine clearance. Hepatic impairment: no adjustment for mild-moderate; in severe hepatic impairment, reduce the maintenance dose (commonly ~50%) because renal clearance may be reduced.

How to Take

Oral use; may be taken with or without food. Measure the dose accurately with an oral syringe/marked measuring device; the solution may be swallowed directly (or diluted in a small amount of water if needed). Shake well before each use.

How to Prepare

N/A - ready-to-use oral solution; no reconstitution required (shake only if the label instructs).

Side Effects

Common Side Effects

Somnolence, dizziness, asthenia/fatigue, headache, irritability/behavioral changes (including aggression), decreased appetite, and nausea; nasopharyngitis can also occur.

Side Effect Frequency

Very common (≥10%): somnolence, asthenia/fatigue, headache, nasopharyngitis. Common (1-10%): dizziness, irritability/nervousness, aggression/hostility, depression/anxiety, insomnia, decreased appetite/anorexia, nausea/vomiting, diarrhea/abdominal pain/dyspepsia, tremor, balance disorder/ataxia/vertigo, rash.

Safety & Warnings

Contraindications

Hypersensitivity to levetiracetam or other pyrrolidone derivatives.

Warnings & Precautions

Monitor for behavioral/psychiatric adverse effects and suicidality; somnolence/fatigue and impaired ability to drive; do not discontinue abruptly; adjust dose in renal impairment; watch for serious skin/hypersensitivity reactions; consider monitoring for hematologic abnormalities when clinically indicated.

Age Restriction

Approved from 1 month of age (indication-dependent; e.g., adjunct for partial-onset seizures from 1 month).

Driving Warning

May Cause Drowsiness

Drug Interactions

Interaction Severity

Clinically relevant interactions are limited; additive CNS depression can occur with alcohol and other sedatives (caution). Levetiracetam has minimal CYP-mediated interactions and generally does not significantly affect oral contraceptives or most antiseizure medicines.

Food Interaction

No clinically significant food restriction; may be taken with or without food.

Special Populations

Breastfeeding

Caution

Children

Dosing is weight-based. Partial-onset seizures: 1 to <6 months: 7 mg/kg twice daily, up to 21 mg/kg twice daily. 6 months to <4 years: 10 mg/kg twice daily, up to 25 mg/kg twice daily. 4 to <16 years: 10 mg/kg twice daily, up to 30 mg/kg twice daily. Primary generalized tonic-clonic seizures (6 to <16 years): 10 mg/kg twice daily, up to 30 mg/kg twice daily.

Elderly

Dose adjustment based on renal function (CrCl); start at lower end of dosing range and titrate carefully; monitor renal function regularly

Kidney Impairment

CrCl 50-79 ml/min: 500-1000 mg twice daily. CrCl 30-49 ml/min: 250-750 mg twice daily. CrCl <30 ml/min: 250-500 mg twice daily. End-stage renal disease on dialysis: 500-1000 mg once daily with 250-500 mg supplemental dose after dialysis

Storage & Patient Advice

Preparation Instructions

N/A - ready-to-use oral solution; no reconstitution required (shake only if the label instructs).

Patient Counseling

Take levetiracetam oral solution exactly as prescribed (often twice daily) at the same times each day; may be taken with or without food. Measure each dose using the provided oral syringe/measuring device (do not use a household spoon). Do not stop suddenly or change the dose without your prescriber (risk of seizure worsening). May cause dizziness/somnolence-avoid driving/operating machinery until you know your response; avoid or limit alcohol and other sedatives. Monitor for behavioral or mood changes (irritability, aggression, depression) or suicidal thoughts and seek medical advice urgently if they occur. If a dose is missed, take it when remembered unless close to the next dose-do not double. Store below 30°C and keep out of reach of children.

Pharmacology

Duration of Effect

Clinical coverage is maintained with twice-daily dosing for immediate-release formulations; adult elimination half-life is ~6-8 hours (longer in renal impairment).

Half-Life

Adults: ~6-8 hours; elderly: may be prolonged (~10-11 hours) due to reduced renal function; children often slightly shorter (~5-7 hours).

Product Information

Available Dosage Forms

For levetiracetam generally: immediate-release tablets, oral solution, and intravenous injection/infusion (some markets also have extended-release tablets). For this SFDA product specifically: oral solution 100 mg/mL in a 150 mL bottle.

Composition per Dose

Each 1 ml: 100 mg levetiracetam

Generic Availability

Yes

OTC Alternatives

No OTC alternative

Reviewed by Al Mujtama Pharmacy Medical Review Team. Last reviewed 15-07-2026